Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

The Biggest News of 2018: TCTMD’s Top 10

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

December 31, 2018

NOACs Significantly Curb Risk of VTE in Cancer Patients

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

December 06, 2018

Quality of Anticoagulation Therapy Lower in Black Patients With A-fib

News Daily News

Quality of Anticoagulation Therapy Lower in Black Patients With A-fib

December 03, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

Top Stories in Cardiology: October 2018

Podcast Heart Sounds

Top Stories in Cardiology: October 2018

October 31, 2018

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

News Daily News

Dabigatran Trials Come Up Short for Stroke of Unknown Cause and Cerebral Venous Thrombosis

October 26, 2018

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

October 04, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No – NOACs Are Strongly Preferred to LAA Closure!

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Good INR Control on Warfarin Doesn’t Necessarily Predict Future Success, Outcomes

News Daily News

Good INR Control on Warfarin Doesn’t Necessarily Predict Future Success, Outcomes

September 13, 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

September 04, 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

August 27, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

August 20, 2018

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

News Daily News

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

August 14, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

Top Stories in Cardiology: July 2018

Podcast Heart Sounds

Top Stories in Cardiology: July 2018

July 25, 2018

Asian Patients With A-fib Don’t Gain Anything From Low-Dose Rivaroxaban

News Daily News

Asian Patients With A-fib Don’t Gain Anything From Low-Dose Rivaroxaban

July 24, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.